一家药店内摆放着诺和诺德生产的 Ozempic 和 Wegovy 药盒。

　　诺和诺德（Novo Nordisk）宣布与美国生物科技公司 Septerna 达成一项独家合作及许可协议，将 “发现、开发和商业化” 用于治疗肥胖症、2 型糖尿病及其他心脏代谢疾病的口服小分子药物。

　　这家 Wegovy（诺和泰）制造商表示，将首先启动四个开发项目，以寻求业务多元化并巩固其在快速增长的肥胖药物市场中的地位。

　　诺和诺德执行副总裁兼首席科学官马库斯・辛德勒（Marcus Schindler）表示：“我们正基于在这一领域的科学领先地位，开发涵盖多种靶点和剂型（包括肽类和小分子）的广泛产品管线。”

海量资讯、精准解读，尽在新浪财经APP

责任编辑：郭明煜

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.